The EPS projection of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) for quarter ended 2016-09-30 is $0.17. Last week, the projection for EPS was $0.17 against target of $0.17, a month earlier. While 2-months ago, this projection was $0.17 versus forecast of $0.17a quarter months earlier, posting a deviation of 0.05%.
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) posted that 18 days earlier, the share price was revised 2 times on upside. In addition, negative revisions were 1.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 1 times. In last one-month and two month the positive revisions were 2 and 2. While in last 120 and 90 days, positive revisions were 3, and 3, correspondingly.
The per-share earnings downgrade for Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) in the preceding 30 and 120 were 0 and 1. While in 60 and 90 days were 0, and 1, in that order.
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) EPS target was $0.17 for the quarter closed 1. It was based on 5 calls. As on 2016-05-03 the EPS was $0.02. The change was $0, posting a deviation of 0%. The price projections gave a standard deviation of 0.04.
Quarterly Sales Estimates
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) sales prediction for the fiscal 2016 stands at $103.056 and the median estimate is at $101.7. Almost 3 analysts gave sales target.
Among this, the highest sales estimate is $110.47 while the lowest target is $97 showing standard deviation of 6.836%.
As many as 3 analysts have positive sales targets revision while 3 reduced sales estimates, posting a deviation of 0%.
Last month, 3 experts have positive sales number revision. Also, 3 research groups lowered the sales projections, posting a deviation of 2.316%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast, posting a deviation of 3.449%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...